Zacks: Brokerages expect Bicycle Therapeutics plc (NASDAQ:BCYC) to post -$0.82 per share earnings
Brokers expect Bicycle Therapeutics plc (NASDAQ:BCYC – Get Rating) to report earnings per share (EPS) of ($0.82) for the current quarter, according to Zacks Investment Research. Eight analysts have made earnings estimates for Bicycle Therapeutics, with estimates ranging from ($1.15) to ($0.67). Bicycle Therapeutics reported earnings per share of ($0.74) in the same quarter last year, which would indicate a negative 10.8% year-over-year growth rate. The company is expected to release its next quarterly results on Monday, January 1.
On average, analysts expect Bicycle Therapeutics to report annual earnings of $3.51 per share for the current fiscal year, with EPS estimates ranging from $5.14 to $2.77. For the next fiscal year, analysts expect the company to post earnings of ($4.09) per share, with EPS estimates ranging from ($6.19) to ($2.95). Zacks EPS calculations are an average average based on a survey of analysts who provide coverage for Bicycle Therapeutics.
Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) last released its quarterly results on Thursday, May 5. The company reported ($0.93) earnings per share for the quarter, missing analyst consensus estimates of ($0.68) by ($0.25). Bicycle Therapeutics had a negative return on equity of 31.61% and a negative net margin of 568.71%.
Several research analysts commented on BCYC’s actions. Needham & Company LLC lowered its price target on Bicycle Therapeutics from $85.00 to $75.00 and set a “buy” rating on the stock in a Tuesday, April 12 research report. Cantor Fitzgerald assumed coverage for Bicycle Therapeutics in a research report on Thursday, April 7. They issued an “overweight” rating and $80.00 price target on the stock. JMP Securities lowered its price target on Bicycle Therapeutics from $85.00 to $70.00 and set a “market outperformance” rating on the stock in a Thursday, March 3 research report. Morgan Stanley began coverage of Bicycle Therapeutics in a research note on Monday, February 14. They issued an “equal weight” rating and $60.00 price target on the stock. Finally, Zacks Investment Research upgraded Bicycle Therapeutics from a “sell” rating to a “hold” rating in a Monday, May 9 research note. Three analysts have rated the stock with a hold rating and nine have issued a buy rating for the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $65.08.
Shares of Bicycle Therapeutics opened at $18.28 on Wednesday. The company has a market capitalization of $542.00 million, a price-earnings ratio of -6.33 and a beta of 0.56. The company has a debt ratio of 0.09, a current ratio of 12.14 and a quick ratio of 12.14. Bicycle Therapeutics has a 52-week low of $16.08 and a 52-week high of $62.08. The stock has a 50-day simple moving average of $31.76 and a 200-day simple moving average of $45.01.
Several hedge funds have recently increased or reduced their stakes in the company. Tybourne Capital Management HK Ltd. increased its stake in Bicycle Therapeutics by 4.9% in the fourth quarter. Tybourne Capital Management HK Ltd. now owns 2,053,804 shares of the company valued at $125,015,000 after purchasing an additional 95,843 shares in the last quarter. Deep Track Capital LP increased its position in shares of Bicycle Therapeutics by 68.7% during the first quarter. Deep Track Capital LP now owns 1,855,993 shares of the company worth $81,441,000 after acquiring an additional 755,993 shares in the last quarter. RTW Investments LP increased its position in shares of Bicycle Therapeutics by 46.8% during the first quarter. RTW Investments LP now owns 1,276,276 shares of the company worth $56,003,000 after acquiring an additional 407,005 shares last quarter. Eventide Asset Management LLC increased its position in shares of Bicycle Therapeutics by 8.6% during the fourth quarter. Eventide Asset Management LLC now owns 1,263,471 shares of the company worth $76,907,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Loomis Sayles & Co. LP increased its position in shares of Bicycle Therapeutics by 12.9% during the first quarter. Loomis Sayles & Co. LP now owns 643,775 shares of the company worth $28,249,000 after acquiring an additional 73,728 shares last quarter. 71.99% of the shares are held by institutional investors.
About Bicycle Therapeutics (Get an evaluation)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin (BTC) conjugate, which is in Phase I/IIa clinical trials targeting tumors that express membrane matrix metalloprotease type 1.
Get a Free Copy of Zacks’ Research Report on Bicycle Therapeutics (BCYC)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Bicycle Therapeutics right now?
Before you consider Bicycle Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Bicycle Therapeutics wasn’t on the list.
Although Bicycle Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here